Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: A Pediatric Oncology Group study

Leukemia

Volumn 14, Issue 5, 2000, Pages 792-795

  Griffin, T C ^a   Shuster, J J ^b   Buchanan, G R ^c   Murphy, S B ^d   Camitta, B M ^e   Amylon, M D ^f  

^a Risk Evaluation to Achieve Cardiovascular Health   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Leukemia; Lymphoblasts; Prognosis; T cell

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; LYMPHOBLAST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PLASMA CLEARANCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0034090983     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401768     Document Type: Article

References (26)

1. Pui C-H. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
2. Pui C-H, Behm FG, Crist WM. Clinical and biologic relevance of immunological marker studies in childhood acute lymphoblastic leukemia. Blood 199.3; 82: 343-362.
3. Pui C-H, Crist WM, Look AT. Biological and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449-1463.
4. Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, Hammond GD. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia. A report from the Children's Cancer Study Group. J Clin Oncol 1989; 7: 1807-1815.
5. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279.
6. Hutchinson R, Bertolone S, Cooper H, , Roskos K, Wells L, Heerema N, Tannous R, Neerhout R, Sather H, Sailer S, Hummell D, Trigg M, Hammond G. Early marrow response predicts outcome for patients with low-risk ALL: results of CCG-1881. Proc Am Soc Clin Oncol 1994; 13: 319 (Abstr. 1051).
7. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol 1996; 14: 389-398.
8. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction therapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 2222-2230.
9. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hematol Bluttransfus 1990; 33: 439-450.
10. Reiter A, Schrappe M, Ludwig W-D, Hiddeman W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multi-center trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
11. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995; 75: 1684-1693.
12. Rautonen J, Hovi L, Siimes MA. Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 1998; 71: 989-991.
13. Gajjar A, Ribero R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, Crist WM, Pui C-H. Persistence of circulating blasts after 1 week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-1295.
14. Legrand O, Marie JP, Cadiou M, Blanc C, Ramon S, Zittoun R. Early cytoreduction: a major prognostic factor in adult acute lymphoblastic leukemia. Leuk lymphoma 1994; 15: 433-438.
15. Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA, Sather HN, Reaman GH, Gaynon PS. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735-746.
16. Crist WM, Shuster JJ, Faletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group study. Blood 1998; 72: 1891-1897.
17. Shuster JJ, Faletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166-173.
18. Uckun F, Steinherz P, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemia cells as a predictor of event-tree survival after chemotherapy of T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1996; 88: 4288-4295.
19. Uckun FM, Gaynon P, Sensel M, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997; 15: 2214-2221.
20. Amylon MD, Shuster J. Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
21. Cox DR: Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
22. Bartolucci AA, Fraser MD. Comparative step-up and composite tests for selecting prognostic indicators associated with survival. Biometrical J 1977; 19: 437-448.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
25. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-1888.
26. Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GAM, Kitchingman GR. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675-681.